Icalziss

Calcium chloride dihydrate, the active ingredient in Icalziss, is a calcium salt presented as a sterile solution for intravenous use. It treats hypocalcemia and calcium deficiency in patients who require rapid electrolyte replacement. GNH USA supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Icalziss is used to correct low calcium levels and support electrolyte balance in clinical settings. - Hypocalcemia: restores serum calcium concentrations to normal ranges. - Calcium deficiency: provides essential calcium for neuromuscular and cardiac function. - Component of intravenous electrolyte solutions: contributes to balanced electrolyte therapy during surgery, critical care, or dialysis.

Adverse reactions may occur with intravenous calcium administration.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Phlebitis: inflammation of the vein used for infusion. - Mild hypercalcemia: transient elevation of serum calcium. - Nausea: occasional feeling of queasiness. - Vomiting: occasional emesis. - Hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm due to excess calcium. - Severe hypercalcemia: marked elevation of calcium causing neurological and cardiac complications. - Tissue necrosis: local tissue death if the solution extravasates. - Anaphylactic reaction: rare severe allergic response requiring immediate treatment.

Careful assessment and monitoring are required when using Icalziss. - Renal function: evaluate before use in patients with renal impairment. - Cardiac status: monitor ECG in patients with known heart disease. - Electrolyte balance: avoid concurrent high‑dose calcium infusions. - Pregnancy: use only if the benefit outweighs potential risk. - Drug compatibility: confirm compatibility with other IV solutions. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Calcium chloride can interact with several medications administered intravenously.

Major Interactions (Avoid): - Calcium carbonate: may precipitate in the IV line. - Bisphosphonates: concurrent IV calcium can reduce therapeutic effect. - Loop diuretics: may increase calcium loss and require dose adjustment.

Moderate Interactions (Monitor Closely): - Digitalis: heightened risk of arrhythmia with elevated calcium. - ACE inhibitors: monitor blood pressure for additive hypotensive effect. - Magnesium sulfate: may alter calcium homeostasis and require monitoring.